Brain Cancer

Temporal Lobe Glioblastoma

Female, 70 years

Patient Internal 368807765

ICD-10 code

C71.2 Malignant Neoplasm of Temporal Lobe

Diagnosis (Incl. Metastases/Stage) and Year

November 2020
Glioblastoma of the Temporal Lobe, WHO IV, KI67 – up to 50%, IDH – wild type; MGMT – Methylated.

Previous Treatment

Radiation therapy, Chemotherapy (Temozolomide)

Prognosis and Survival Expectation

The prognosis remains poor, with a median survival of ~14 months from diagnosis.

Treatment Provided

Autologous DCV (6 doses) and CIK (4 doses) over a period of 5 months. Additionally, the patient received Xenogeneic Preventive and Therapeutic Anti-Cancer Vaccines (PTAC) (10 Vaccines).

Patient Survival/Condition and Year
Date of Review: 01/12/2023

The patient has survived for 30 months since the diagnosis. It can be concluded that the addition of Immunotherapy, alongside Chemotherapy and Radiation Therapy, has extended patient survival by an
estimate of around 16 months.